Immunethep Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 22

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $2M

  • Investors
  • 10

Immunethep General Information

Description

Developer of a biotechnology company intended to develop bacterial immunotherapies based on the discovery of a virulence mechanism shared by different bacteria that cause life-threatening infections. The company offers therapies, including the development of neonatal vaccines to protect neonates from bacterial infections inside the mother's womb, enabling patients to develop their immunity and prevent multi-bacterial infections and diseases through advanced healthcare methods.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Biocant Park Nucleo 04 Lote 3
  • Cantanhede, 3060-197
  • Portugal
+351 231
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Biocant Park Nucleo 04 Lote 3
  • Cantanhede, 3060-197
  • Portugal
+351 231

Immunethep Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Immunethep Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Later Stage VC 25-Feb-2025 $2M Completed Generating Revenue
10. Later Stage VC 01-Jan-2024 Completed Generating Revenue
9. Accelerator/Incubator Completed Pre-Clinical Trials
8. Project Financing 04-Jan-2023 Completed Pre-Clinical Trials
7. Grant 15-Jun-2022 Completed Pre-Clinical Trials
6. Later Stage VC Completed Pre-Clinical Trials
5. Later Stage VC 18-Oct-2018 Completed Pre-Clinical Trials
4. Grant 23-Oct-2017 Completed Pre-Clinical Trials
3. Grant 31-Mar-2017 $300K Completed Startup
2. Seed Round 30-Mar-2015 Completed Startup
To view Immunethep’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Immunethep Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a biotechnology company intended to develop bacterial immunotherapies based on the discovery of a virulence
Drug Discovery
Cantanhede, Portugal
22 As of 2026

Frederiksberg, Denmark
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Immunethep Competitors (1)

One of Immunethep’s competitors is MinervaX, a Venture Capital-Backed company based in Frederiksberg, Denmark.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
MinervaX Venture Capital-Backed Frederiksberg, Denmark
You’re viewing 1 of 1 competitors. Get the full list »

Immunethep Patents

Immunethep Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024337266-A1 Products and methods for inducing immune responses to bacteria Pending 06-Sep-2023
EP-4773809-A1 Products and methods for inducing immune responses to bacteria Pending 06-Sep-2023
WO-2025051845-A1 Products and methods for inducing immune responses to bacteria Inactive 06-Sep-2023
EP-3967326-A1 Immunogenic compositions Inactive 10-Sep-2020
WO-2022053639-A1 Immunogenic compositions Inactive 10-Sep-2020 A61K39/12
To view Immunethep’s complete patent history, request access »

Immunethep Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Immunethep Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
CARB-X University Minority
Snap Partners Venture Capital Minority
Beta Capital (Portugal) Venture Capital Minority
European Innovation Council Accelerator/Incubator Minority
Gates Foundation Not-For-Profit Venture Capital
You’re viewing 5 of 10 investors. Get the full list »

Immunethep FAQs

  • When was Immunethep founded?

    Immunethep was founded in 2013.

  • Where is Immunethep headquartered?

    Immunethep is headquartered in Cantanhede, Portugal.

  • What is the size of Immunethep?

    Immunethep has 22 total employees.

  • What industry is Immunethep in?

    Immunethep’s primary industry is Drug Discovery.

  • Is Immunethep a private or public company?

    Immunethep is a Private company.

  • What is Immunethep’s current revenue?

    The current revenue for Immunethep is .

  • How much funding has Immunethep raised over time?

    Immunethep has raised $2.85M.

  • Who are Immunethep’s investors?

    CARB-X, Snap Partners, Beta Capital (Portugal), European Innovation Council, and Gates Foundation are 5 of 10 investors who have invested in Immunethep.

  • Who are Immunethep’s competitors?

    MinervaX is a competitor of Immunethep.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process